Pfizer in den Nachrichten
Entwicklung innovativer Gesundheitstherapien
Tamtam hat 20 aktuelle Artikel über Pfizer gefunden.
- No, Pfizer CEO did not say it planned to halve the world’s population
- What Drives Our Scientists: Dafydd Owen
- Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027
- Pfizer's Bourla Says His Future Rivals Are Chinese, and Washington Is Still Deciding What to Do About It
- EUROCONTROL blocks the amounts owed to ROMATSA again / The garnishment was imposed at Pfizer’s request in the litigation concerning COVID-19 vaccines
- SRX Global comments on Pfizer-Starna deal amid CERo acquisition
- Pfizer's $330 million upfront deal backs three immune-cell programs, separate from SRX's pending CERo acquisition.
- Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill
- Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
- Pfizer Bets $330 Million on China's In Vivo CAR-T Platform as FDA Approves Two Rare Disease Treatments
- Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak.
- Corporate America demands a stronger voice on AI
- Missed Pfizer's Rally? Here Is What Holders Saw
- Pfizer Elevates 26-Year Veteran Eric Aaronson to GC Role
- Can New Products and Acquisitions Revive Pfizer's Growth Story?
- Pharmerging Market 2026-2029 | Pfizer Inc., Sanofi,
- 3 ETFs That Give You Pfizer With Very Different Mixes
- Why Pfizer’s CEO Is Optimistic About The Future Of Immigration In the U.S.
- Learning at the Rate of Evidence: How AI Is Reshaping R&D at Pfizer
- Most-Active S&P 500 Stocks: Ford, Super Micro, Pfizer Lead Session Volume
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Pfizer?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden